NI201100155A - Composiciones y métodos para el tratamiento prolongado con aminopiridinas - Google Patents

Composiciones y métodos para el tratamiento prolongado con aminopiridinas

Info

Publication number
NI201100155A
NI201100155A NI201100155A NI201100155A NI201100155A NI 201100155 A NI201100155 A NI 201100155A NI 201100155 A NI201100155 A NI 201100155A NI 201100155 A NI201100155 A NI 201100155A NI 201100155 A NI201100155 A NI 201100155A
Authority
NI
Nicaragua
Prior art keywords
aminopyridines
methods
compositions
prolonged treatment
prolonged
Prior art date
Application number
NI201100155A
Other languages
English (en)
Spanish (es)
Inventor
Cohen Ron
R Blight Andrew
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201100155(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of NI201100155A publication Critical patent/NI201100155A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NI201100155A 2009-02-11 2011-08-09 Composiciones y métodos para el tratamiento prolongado con aminopiridinas NI201100155A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15167909P 2009-02-11 2009-02-11
US25956309P 2009-11-09 2009-11-09
US28587209P 2009-12-11 2009-12-11
US28895309P 2009-12-22 2009-12-22
US29925910P 2010-01-28 2010-01-28

Publications (1)

Publication Number Publication Date
NI201100155A true NI201100155A (es) 2012-02-16

Family

ID=42562065

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201100155A NI201100155A (es) 2009-02-11 2011-08-09 Composiciones y métodos para el tratamiento prolongado con aminopiridinas

Country Status (22)

Country Link
US (3) US20120029035A1 (enExample)
JP (1) JP2012517449A (enExample)
KR (3) KR20120000560A (enExample)
CN (2) CN102046174A (enExample)
AR (1) AR075413A1 (enExample)
AU (2) AU2010213663A1 (enExample)
BR (2) BRPI1000031A2 (enExample)
CA (1) CA2751581A1 (enExample)
CL (1) CL2011001927A1 (enExample)
CO (1) CO6440534A2 (enExample)
EA (1) EA022755B1 (enExample)
EC (1) ECSP11011311A (enExample)
IL (1) IL214500A0 (enExample)
MX (1) MX2011008485A (enExample)
NI (1) NI201100155A (enExample)
NZ (1) NZ595046A (enExample)
PE (1) PE20120791A1 (enExample)
SG (2) SG10201609184PA (enExample)
TN (1) TN2011000403A1 (enExample)
TW (2) TW201032809A (enExample)
UY (2) UY32444A (enExample)
WO (2) WO2010093838A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20150111930A1 (en) * 2013-10-23 2015-04-23 Afgin Pharma, Llc Topical regional neuro-affective therapy
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
CN102442942A (zh) * 2010-10-08 2012-05-09 天津和美生物技术有限公司 4-氨基吡啶的多晶型物及其制备和应用
EP2667869A1 (en) * 2011-01-28 2013-12-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
EP2814492A1 (en) * 2012-02-13 2014-12-24 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
CN105993016B (zh) * 2014-02-04 2020-01-10 奥普蒂马塔公司 用于为具有特定疾病的个体规划医疗的计算机化系统
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
WO2022124946A1 (ru) * 2020-12-10 2022-06-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые полиморфные формы 4-аминопиридина и их фармацевтическое применение
CN112914884B (zh) * 2021-01-19 2022-02-11 重庆火后草科技有限公司 通过稳态时长置信度测量睡眠状态下的体重值的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions

Also Published As

Publication number Publication date
AU2010213663A1 (en) 2011-09-29
NZ595046A (en) 2013-10-25
CL2011001927A1 (es) 2012-07-20
BRPI1000030A2 (pt) 2018-02-14
ECSP11011311A (es) 2011-10-31
EA201171043A1 (ru) 2012-02-28
AU2016219650A1 (en) 2016-09-15
KR20120000560A (ko) 2012-01-02
MX2011008485A (es) 2011-11-04
WO2010093839A1 (en) 2010-08-19
PE20120791A1 (es) 2012-07-08
SG10201609184PA (en) 2016-12-29
UY32445A (es) 2010-09-30
AU2016219650B2 (en) 2018-05-10
KR20180114250A (ko) 2018-10-17
CN102046174A (zh) 2011-05-04
CA2751581A1 (en) 2010-08-19
BRPI1000031A2 (pt) 2018-02-14
US20170319562A1 (en) 2017-11-09
SG173641A1 (en) 2011-09-29
TN2011000403A1 (en) 2013-03-27
TW201034665A (en) 2010-10-01
KR20170034452A (ko) 2017-03-28
AU2016219650C1 (en) 2018-08-23
AR075413A1 (es) 2011-03-30
EA022755B1 (ru) 2016-02-29
CO6440534A2 (es) 2012-05-15
WO2010093838A1 (en) 2010-08-19
TW201032809A (en) 2010-09-16
IL214500A0 (en) 2011-09-27
UY32444A (es) 2010-09-30
CN101896182A (zh) 2010-11-24
US20120029035A1 (en) 2012-02-02
JP2012517449A (ja) 2012-08-02
US20150313886A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
ECSP11011311A (es) Composiciones y metodos para terapia prolongada con aminopiridinas
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
ECSP14013224A (es) Pirimidinas anilladas sustituidas y uso de las mismas
CL2011000668A1 (es) Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
UY35115A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
AR089993A1 (es) Macrociclos peptidomimeticos
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
CL2012001714A1 (es) Compuestos derivados de pirrol[3.4-b]piridin-5-ona, inhibidores de pi3k; composicion farmaceutica que los comprende; y uso para el tratamiento de enfermedades tales como alzheimer, epilepsia, esclerosis multiple, parkinson, entre otras.
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
IN2014DN06104A (enExample)
MX339533B (es) Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp).
UY35652A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
MY181891A (en) Novel bicyclic pyridinones
PH12015500746A1 (en) Benzamides
CL2014000641A1 (es) Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras.
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
IN2014DN03298A (enExample)
PT2632475T (pt) Composições para o tratamento de úlceras periféricas de várias origens
EA201300733A1 (ru) Рекомбинантные микобактерии в качестве вакцины
AR078323A1 (es) Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple